SG10201510800PA - Purification of flaviviruses - Google Patents

Purification of flaviviruses

Info

Publication number
SG10201510800PA
SG10201510800PA SG10201510800PA SG10201510800PA SG10201510800PA SG 10201510800P A SG10201510800P A SG 10201510800PA SG 10201510800P A SG10201510800P A SG 10201510800PA SG 10201510800P A SG10201510800P A SG 10201510800PA SG 10201510800P A SG10201510800P A SG 10201510800PA
Authority
SG
Singapore
Prior art keywords
flaviviruses
purification
Prior art date
Application number
SG10201510800PA
Inventor
Sophia Mundle
Stephen Anderson
Original Assignee
Sanofi Pasteur Biologics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Biologics Llc filed Critical Sanofi Pasteur Biologics Llc
Publication of SG10201510800PA publication Critical patent/SG10201510800PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2315/00—Details relating to the membrane module operation
    • B01D2315/10—Cross-flow filtration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2315/00—Details relating to the membrane module operation
    • B01D2315/16—Diafiltration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Water Supply & Treatment (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG10201510800PA 2012-01-09 2013-01-08 Purification of flaviviruses SG10201510800PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261584461P 2012-01-09 2012-01-09

Publications (1)

Publication Number Publication Date
SG10201510800PA true SG10201510800PA (en) 2016-01-28

Family

ID=48781838

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201403891SA SG11201403891SA (en) 2012-01-09 2013-01-08 Purification of flaviviruses
SG10201510800PA SG10201510800PA (en) 2012-01-09 2013-01-08 Purification of flaviviruses

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201403891SA SG11201403891SA (en) 2012-01-09 2013-01-08 Purification of flaviviruses

Country Status (6)

Country Link
US (1) US20150030565A1 (en)
EP (1) EP2802650A4 (en)
AU (1) AU2013208187B2 (en)
CA (1) CA2896931A1 (en)
SG (2) SG11201403891SA (en)
WO (1) WO2013106337A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015195453A2 (en) 2014-06-16 2015-12-23 Emd Millipore Corporation Methods for increasing the capacity of flow-through processes
US10207225B2 (en) 2014-06-16 2019-02-19 Emd Millipore Corporation Single-pass filtration systems and processes
ES2742704T3 (en) 2014-06-25 2020-02-17 Emd Millipore Corp Compact filter elements, modules and systems, spirally wound
ES2935333T3 (en) 2014-08-29 2023-03-06 Emd Millipore Corp Processes for filtering liquids using single pass tangential flow filtration systems and tangential flow filtration systems with recirculation of retentate
US10195550B2 (en) 2014-08-29 2019-02-05 Emd Millipore Corporation Single pass tangential flow filtration systems and tangential flow filtration systems with recirculation of retentate
WO2017053239A1 (en) * 2015-09-22 2017-03-30 Sanofi Pasteur Biologics, Llc Purification of respiratory syncytial virus
KR20200088326A (en) * 2017-10-16 2020-07-22 세럼 인스티튜트 오브 인디아 프라이비트 리미티드 In particular, a stable vaccine composition comprising a live attenuated recombinant flavivirus and a method for manufacturing the same
JP2021528999A (en) * 2018-07-04 2021-10-28 プロバイオジェン アーゲー Envelope virus purification method
WO2021174059A1 (en) 2020-02-27 2021-09-02 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
GB202215814D0 (en) * 2022-10-26 2022-12-07 Cytiva Bioprocess R & D Ab A chromatography device, system, and use thereof for analytic separation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889632A (en) 1987-12-10 1989-12-26 Ceskoslovenska Akademie Ved Macroporous polymeric membranes for the separation of polymers and a method of their application
EP0777725B1 (en) 1994-08-23 2001-04-04 Bia Separations D.O.O. Process and device for the rapid separation and/or conversion of substrates
US6962708B1 (en) 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
US6207439B1 (en) * 1997-03-25 2001-03-27 Center For Disease Control Purification of Japanese encephalitis virus
DE69927792T2 (en) 1998-02-27 2006-07-20 Bia Separations D.O.O. CHROMATOGRAPHIC DEVICE
AU2001281906A1 (en) 2000-06-27 2002-01-08 Bia Separations D.O.O. A chromatography material and a process of manufacturing that material
US20040259224A1 (en) 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
CN101155915B (en) * 2005-04-11 2013-12-04 克鲁塞尔荷兰公司 Virus purification using ultrafiltration
RU2465326C2 (en) * 2005-04-24 2012-10-27 Санофи Пастер Байолоджикс Ко Recombinant flaviviral vaccines
WO2006122964A1 (en) * 2005-05-19 2006-11-23 Crucell Holland B.V. Methods for the production of a whole-inactivated west nile virus vaccine
AU2007217352B2 (en) * 2006-02-27 2013-09-26 The Board Of Regents Of The University Of Texas System Pseudoinfectious flavivirus and uses thereof
EP1878791A1 (en) * 2006-07-11 2008-01-16 Bia Separations D.O.O. Method for influenza virus purification
BRPI0714721A2 (en) 2006-07-14 2013-04-24 Sanofi Pasteur Biologics Co construction of recombinant virus vaccines by direct transponder-mediated insertion of foreign immunological determinants into vector virus proteins
WO2008094674A1 (en) * 2007-01-31 2008-08-07 Sanofi Pasteur Biologics Co. Recombinant bicistronic flavivirus vectors
SG188891A1 (en) * 2008-03-14 2013-04-30 Sanofi Pasteur Biologics Co Replication-defective flavivirus vaccines and vaccine vectors
EP2408477A4 (en) 2009-03-16 2013-03-27 Sanofi Pasteur Biologics Llc Replication-defective flavivirus vaccine vectors against respiratory syncytial virus
US20110142863A1 (en) * 2009-12-16 2011-06-16 Millipore Corporation Flow through purification processes for large biomolecules

Also Published As

Publication number Publication date
EP2802650A1 (en) 2014-11-19
SG11201403891SA (en) 2014-08-28
WO2013106337A1 (en) 2013-07-18
US20150030565A1 (en) 2015-01-29
CA2896931A1 (en) 2013-07-18
AU2013208187B2 (en) 2018-07-12
AU2013208187A1 (en) 2014-07-24
EP2802650A4 (en) 2015-09-30

Similar Documents

Publication Publication Date Title
IL287057A (en) Purification of iduronate-2 sulfatase
EP2826473A4 (en) Novel use of patchoulol
SG11201403891SA (en) Purification of flaviviruses
ZA201406082B (en) Use of ccr3-inhibitors
EP2917314A4 (en) Composition of oligomerate
IL263162B (en) Purification of cystathionine beta-synthase
IL236312A0 (en) Preparation of 18f-fluciclovine
EP2881113A4 (en) New application of pogostone
HK1202053A1 (en) Treatment of liver conditions
SG11201406800UA (en) Purification of air
PL2888228T3 (en) Inhibitors of cd40-traf6 interaction
EP2892529A4 (en) Uses of (-)-perhexiline
SG11201504201RA (en) Purification of x-ray contrast agents
GB201207907D0 (en) Treatment of depression
IL233740A0 (en) Treatment of liver conditions
TWM433525U (en) Structure of calorifier